Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2014, Article ID 767652, 4 pages
http://dx.doi.org/10.1155/2014/767652
Clinical Study

Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin

Department of Surgery, Chita City Hospital, 2-1 Nagai, Shinchi, Chita, Aichi 478-0017, Japan

Received 1 June 2014; Accepted 17 September 2014; Published 24 September 2014

Academic Editor: Bruno Vincenzi

Copyright © 2014 Akira Ouchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Loehrer and L. H. Einhorn, “Drugs five years later. Cisplatin.,” Annals of Internal Medicine, vol. 100, no. 5, pp. 704–713, 1984. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Go and A. A. Adjei, “Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 409–422, 1999. View at Google Scholar · View at Scopus
  3. R. S. Finley, C. L. Fortner, and W. R. Grove, “Cisplatin nephrotoxicity: a summary of preventative interventions,” Drug Intelligence and Clinical Pharmacy, vol. 19, no. 5, pp. 362–367, 1985. View at Google Scholar · View at Scopus
  4. A. Sobrero, A. Guglielmi, C. Aschele, and R. Rosso, “Current strategies to reduce cisplatin toxicity,” Journal of Chemotherapy, vol. 2, no. 1, pp. 3–7, 1990. View at Google Scholar · View at Scopus
  5. T. L. Cornelison and E. Reed, “Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin,” Gynecologic Oncology, vol. 50, no. 2, pp. 147–158, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Pinzani, F. Bressolle, I. J. Haug, M. Galtier, J. P. Blayac, and P. Balmes, “Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review,” Cancer Chemotherapy and Pharmacology, vol. 35, no. 1, pp. 1–9, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Tiseo, O. Martelli, A. Mancuso et al., “Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma,” Tumori, vol. 93, no. 2, pp. 138–144, 2007. View at Google Scholar · View at Scopus
  8. H. Horinouchi, K. Kubota, H. Itani et al., “Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study,” Japanese Journal of Clinical Oncology, vol. 43, no. 11, Article ID hyt122, pp. 1105–1109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Hotta, N. Takigawa, A. Hisamoto-Sato et al., “Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002,” Japanese Journal of Clinical Oncology, vol. 43, no. 11, Article ID hyt128, pp. 1115–1123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. DuBois and E. F. DuBois, “A formula to estimate the approximate surface area if height and weight be known,” Archives of Internal Medicine, vol. 17, pp. 863–871, 1916. View at Google Scholar
  11. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Marceau, M. Poirier, E. Masson, and E. Beaulieu, “High incidence of nephrotoxicity with cisplatin therapy despite adequate hydration: risk factor correlations,” in Proceedings of the American Society of Clinical Oncology, 1999, abstract 840.
  13. M. Dollinger, “Guidelines for hospitalization for chemotherapy,” The Oncologist, vol. 1, pp. 107–111, 1996. View at Google Scholar
  14. Y. Sasaki, T. Tamura, K. Eguchi et al., “Pharmacokinetics of (glycolato-0,0')-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 4, pp. 243–246, 1989. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Stewart, C. S. Dulberg, N. Z. Mikhael, M. D. Redmond, V. A. J. Montpetit, and R. Goel, “Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods,” Cancer Chemotherapy and Pharmacology, vol. 40, no. 4, pp. 293–308, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Mor, M. Z. Stalker, R. Gralla et al., “Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial,” Journal of Clinical Epidemiology, vol. 41, no. 8, pp. 771–785, 1988. View at Publisher · View at Google Scholar · View at Scopus